• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

唑来膦酸对耐紫杉烷、雌莫司汀、卡铂和地塞米松的转移性激素难治性前列腺癌的作用。

Effect of zoledronic acid on metastatic hormone-refractory prostate cancer resistant to taxane, estramustine, carboplatin, and dexamethasone.

作者信息

Kikuno Nobuyuki, Urakami Shinji, Nakamura Shigeru, Shiina Hiroaki, Igawa Mikio

机构信息

Department of Urology, Shimane University School of Medicine, Izumo, Japan.

出版信息

Int J Urol. 2007 Jan;14(1):82-4. doi: 10.1111/j.1442-2042.2006.01566.x.

DOI:10.1111/j.1442-2042.2006.01566.x
PMID:17199867
Abstract

This case report demonstrates the effect of zoledronic acid (ZA) on a patient with bone metastatic hormone-refractory prostate cancer (HRPC) resistant to taxane, estramustine phosphate, carboplatin, and dexamethasone. The pathogenesis, diagnosis, and management of bone metastasis on HRPC are also reviewed.

摘要

本病例报告展示了唑来膦酸（ZA）对一名患有骨转移性激素难治性前列腺癌（HRPC）患者的疗效，该患者对紫杉烷、磷酸雌莫司汀、卡铂和地塞米松耐药。本文还回顾了HRPC骨转移的发病机制、诊断和治疗。

相似文献

1
Effect of zoledronic acid on metastatic hormone-refractory prostate cancer resistant to taxane, estramustine, carboplatin, and dexamethasone.唑来膦酸对耐紫杉烷、雌莫司汀、卡铂和地塞米松的转移性激素难治性前列腺癌的作用。
Int J Urol. 2007 Jan;14(1):82-4. doi: 10.1111/j.1442-2042.2006.01566.x.
2
Docetaxel and beyond.
Eur Urol. 2007 May;51(5):1159-61. doi: 10.1016/j.eururo.2007.01.007. Epub 2007 Jan 10.
3
A prospective, multicenter, open-label trial of zoledronic acid in patients with hormone refractory prostate cancer.一项关于唑来膦酸治疗激素难治性前列腺癌患者的前瞻性、多中心、开放标签试验。
Yonsei Med J. 2007 Dec 31;48(6):1001-8. doi: 10.3349/ymj.2007.48.6.1001.
4
Complete clinical and biological response to zoledronic acid in castrate-resistant prostate cancer metastatic to bone.唑来膦酸治疗去势抵抗性前列腺癌骨转移的完全临床和生物学反应。
Anticancer Drugs. 2012 Jan;23(1):141-2. doi: 10.1097/CAD.0b013e32834bede5.
5
Bisphosphonate therapy for hormone refractory prostate cancer with bone metastasis.双膦酸盐疗法用于治疗伴有骨转移的激素难治性前列腺癌。
J Urol. 2003 Jan;169(1):281-2. doi: 10.1016/S0022-5347(05)64093-1.
6
[The effect of bisphosphonates on bone metastasis of hormone-refractory prostate cancer].[双膦酸盐对激素难治性前列腺癌骨转移的影响]
Hinyokika Kiyo. 2006 Jun;52(6):491-4.
7
[Strategy in advanced castration-resistant prostate cancer].[晚期去势抵抗性前列腺癌的治疗策略]
Bull Cancer. 2012 Jul;99 Suppl 1:S37-45. doi: 10.1684/bdc.2012.1562.
8
Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.多西他赛、磷酸雌莫司汀和唑来膦酸联合治疗雄激素非依赖性转移性前列腺癌：疗效、安全性及临床获益评估
Urology. 2005 Jan;65(1):126-30. doi: 10.1016/j.urology.2004.08.041.
9
Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade.唑来膦酸对联合雄激素阻断治疗伴骨转移的激素敏感性前列腺癌患者血清前列腺特异性抗原变化的附加作用。
Int J Urol. 2012 Feb;19(2):169-73. doi: 10.1111/j.1442-2042.2011.02914.x. Epub 2011 Nov 29.
10
Efficacy of combined androgen blockade with zoledronic acid treatment in prostate cancer with bone metastasis: the ZABTON-PC (zoledronic acid/androgen blockade trial on prostate cancer) study.唑来膦酸联合雄激素阻断治疗前列腺癌骨转移的疗效：ZABTON-PC（唑来膦酸/雄激素阻断治疗前列腺癌试验）研究。
Anticancer Res. 2013 Sep;33(9):3837-44.